Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1) entered recently clinical trials for treatment of gliomas. Here, the authors apply a MRS imaging method for 2HG detection and assessement of the pharmacodynamic effects of the mutant IDH1 inhibitor (IDH305) in 8 mutant IDH1 glioma patients.

Saved in:
Bibliographic Details
Main Authors: Ovidiu C. Andronesi, Isabel C. Arrillaga-Romany, K. Ina Ly, Wolfgang Bogner, Eva M. Ratai, Kara Reitz, A. John Iafrate, Jorg Dietrich, Elizabeth R. Gerstner, Andrew S. Chi, Bruce R. Rosen, Patrick Y. Wen, Daniel P. Cahill, Tracy T. Batchelor
Format: article
Language:EN
Published: Nature Portfolio 2018
Subjects:
Science
Q
Online Access:https://doaj.org/article/b6420b3093174f1f828f783b189caae2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/b6420b3093174f1f828f783b189caae2

Similar Items